Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,915 | 361 | 2,516 |
| Samples | 718 | 124 | 584 |
| Peptides | 634 | 92 | 542 |
Function
NUP98 · Nucleoporin 98 and 96 precursor
Nuclear pore complexes (NPCs) regulate the transport of macromolecules between the nucleus and cytoplasm, and are composed of many polypeptide subunits, many of which belong to the nucleoporin family. This gene belongs to the nucleoporin gene family and encodes a 186 kDa precursor protein that undergoes autoproteolytic cleavage to generate a 98 kDa nucleoporin and 96 kDa nucleoporin. The 98 kDa nucleoporin contains a Gly-Leu-Phe-Gly (GLGF) repeat domain and participates in many cellular processes, including nuclear import, nuclear export, mitotic progression, and regulation of gene expression. The 96 kDa nucleoporin is a scaffold component of the NPC. Proteolytic cleavage is important for targeting of the proteins to the NPC. Translocations between this gene and many other partner genes have been observed in different leukemias. Rearrangements typically result in chimeras with the N-terminal GLGF domain of this gene to the C-terminus of the partner gene. Alternative splicing results in multiple transcript variants encoding different isoforms, at least two of which are proteolytically processed. Some variants lack the region that encodes the 96 kDa nucleoporin. [provided by RefSeq, Feb 2016].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 601 amino-acid changes on canonical ENST00000324932 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NUP98 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NUP98 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 8/42 19% | 33/612 5% |
| Glioblastoma | 6/98 6% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Melanoma | 9/210 4% | 66/1899 3% |
| Gastric Carcinoma | 5/74 7% | 48/1809 3% |
| Colorectal Carcinoma | 14/143 10% | 77/3239 2% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 31/1390 2% |
| Other Solid Cancers | 7/94 7% | 31/1515 2% |
| Burkitts Lymphoma | 1/32 3% | 4/196 2% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 16/810 2% |
| Bladder Carcinoma | 1/58 2% | 19/956 2% |
| Ovarian Carcinoma | 8/109 7% | 12/998 1% |
| Cervical Carcinoma | 1/35 3% | 7/422 2% |
| Thyroid Gland Carcinoma | 0/45 0% | 28/1592 2% |
| Neuroendocrine Tumour | 6/154 4% | 5/577 1% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 9/752 1% |
| Hepatocellular Carcinoma | 0/46 0% | 29/2210 1% |
| Breast Carcinoma | 6/144 4% | 36/3264 1% |
| Plasma Cell Myeloma | 2/44 5% | 2/305 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Biliary Tract Carcinoma | 0/54 0% | 10/950 1% |
| Pancreatic Carcinoma | 2/89 2% | 15/1611 1% |
| Non-Cancerous | 1/104 1% | 8/830 1% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Glioma | 2/52 4% | 17/2127 1% |
Mutation Distribution
Where NUP98 is mutated · all tissues, split by cell line vs tissue
How many mutations in NUP98 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,915 mutations in NUP98
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|